drugset / Trial / NCT00617058
Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine
Phase 2
Terminated
1 enrolled
University of North Carolina, Chapel Hill
Foundation of Hope, North Carolina · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the relative risks and benefits of two approaches to the control of weight gain and other negative side effects in children and adolescents on 2nd generation antipsychotics (SGA): * Healthy lifestyle instruction (nutritional and physical activity surveillance and advice) + continuation of current SGA; * Add the diabetes drug, metformin + continuation of current SGA.
Timeline
- Start
- 2007-03
- Primary completion
- 2010-06
- Completion
- 2010-09
Outcome
Outcome not reported
Stopped: “Terminated in lieu of similar,competing large, multi-site study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 250 mg | — |
| Subject | Metformin | Small molecule | 2000 mg | — |
Indications
No indication recorded.